MindMed

Today we are presenting a poster at AMCP Nexus 2024 on the economic burden of generalized anxiety disorder (GAD) in the U.S. These findings support efforts to effectively diagnose GAD and treat symptoms to potentially mitigate the multifaceted burden among the GAD population. Learn more here: https://lnkd.in/e9YXkeUp #AMCPNexus???

This year, #WorldMentalHealthDay is centered on the relationship between work and mental health. We support the World Federation for Mental Health’s efforts and strive to combine know-how and compassion in all we do, both in our workplace and in the work we do to rethink brain health.

Learn how MindMed is advancing the therapeutic potential of psychedelics and novel compounds to address critical needs in brain health: mindmed.co #MentalHealth #Neuroscience #Psychedelics

LSD is classified as a classic psychedelic because it alters perception, mood, and cognition. These effects are due to its interaction with serotonin receptors in the brain, particularly those influencing mood and perception. We believe LSD may be beneficial for the treatment of anxiety and depression because it has the potential to disrupt rigid thought patterns and promote a state of openness and emotional re-examination.

At MindMed, our dedication to advancing mental health treatment is rooted in a strong commitment to scientific rigor. As our Chief Medical Officer, Dr. Dan Karlin, highlights, we ensure every discovery is validated through meticulous research. Our approach involves: ?? Robust Clinical Trials: Conducting comprehensive trials to test the safety and efficacy of our drug candidates. ?? Innovative Research: Leveraging advanced scientific methodologies to explore new treatment avenues. ?? Collaborative Expertise: Partnering with leading experts and institutions to enhance the quality and impact of our research. #mentalhealth #innovation #healthcare

This week, Phong T. Duong VP, Global Market Access and Health Economics presented?an analysis of?retrospective study data from the 2022 US National Health and Wellness Survey (NHWS) indicating that even small increases in the severity of GAD?can?significantly worsen the quality of life for patients living with it, suggesting a reduction in symptoms?may?have a meaningful impact on a patient's quality of life. These results were presented at ECNP, Europe’s premier scientific meeting for disease-oriented brain research?being held this week in Milan. Learn more?here: https://lnkd.in/dPwqBsQu ? #ECNP2024 #AnxietyAwareness

Our Chief Medical Officer, Dan Karlin, will be leading a workshop at the 7th Neuropsychiatric Drug Development Summit coming up on September 24. Dan will be joined by other leaders in the field to discuss navigating regulatory challenges for psychedelic drugs, exploring optimal trial designs, and new regulatory frameworks. We’re looking forward to the insights and collaborative discussions at this event. See you there! #Neuropsychiatry #DrugDevelopment #HealthcareInnovation

Our CEO, Robert Barrow, and CMO Dan Karlin will be part of a fireside chat at the 2024 Cantor Global Healthcare Conference tomorrow in New York. This conference brings together top innovators across biotechnology, pharmaceuticals, and healthcare technology to discuss advancements and explore trends shaping the future of healthcare. A big thank you to Cantor Fitzgerald for hosting such a valuable conference! #CantorHCC #HealthcareInnovation Tune-in here:https://lnkd.in/dryf7CVr

On today’s 9/11 National Day of Service and Remembrance, we honor those we lost and the countless people who bravely rose to serve in response to the tragic events. In the spirit of the unity and compassion that brought us together in the aftermath, we joined 9/11 Day in helping pack 700,000 meals to support those facing food insecurity in the Greater Philadelphia community. #NeverForget